Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations

the ONA take:

Afatinib is clinically active and well tolerated in many tyrosine kinase inhibitor (TKI)-pretreated patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations, according to a new study published in the journal The Oncologist.

For the study, researchers enrolled 60 patients with advanced or metastatic, histologically confirmed NSCLC that progressed after at least one line of chemotherapy and one line of EGFR TKI treatment. Researchers identified a total of 66 uncommon EGFR mutations, including 30 T790M mutations. Most patients received the oral TKI as third- or fourth-line treatment.

Results showed that median time to treatment failure was 3.8 months in patients with uncommon mutations compared with 5.1 months in those with common mutations. The study demonstrated pronounced activity with a time to treatment failure of greater than 12 months in patients with E709X mutations.

“Although indirectly assessed, the results indicate that patients with uncommon EGFR mutations can derive benefit from treatment with the irreversible ErbB family blocker afatinib, even in some cases of tumors harboring resistance-mediating exon 20 mutations,” the authors write.

Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations
Afatinib active in many TKI-pretreated patients with NSCLC and uncommon EGFR mutations
This analysis consists of a large database of non-small cell lung cancer patients with uncommon EGFR mutations who were previously treated with reversible EGFR tyrosine kinase inhibitors. Although indirectly assessed, the results indicate that patients with uncommon EGFR mutations can derive benefit from treatment with the irreversible ErbB family blocker afatinib, even in some cases of tumors harboring resistance-mediating exon 20 mutations. In this study, adverse events were modest and consistent with previous reports on afatinib.
READ FULL ARTICLE From theoncologist.alphamedpress.org
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs